Subscribe To

Price Alert Latest News Economic Calendar News

BNTX / BioNTech co-founder Özlem Türeci on how Covid vaccine will help future drug developments

The scientist behind the Pfizer-BioNTech Covid vaccine, Özlem Türeci, speaks to CNBC's Tania Bryer after the 2021 WIRED Health:Tech event, about what the public and private sectors need to do to achieve vaccine equity and how lessons learned from development and regulatory processes will support future treatments for other diseases. Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z Like our Facebook page https://www.facebook.com/cnbcinternational Follow us on Instagram https://www.instagram.com/cnbcinternational/ Follow us on Twitter https://twitter.com/cnbci Read More

Demo Live Account See Partner Details

Content Topics

Biontech

Co

Founder

Zlem

Treci

Covid

Vaccine

Will

Help

Co founder

zlem

T reci

Future

Developments

Stock

BNTX

Posted: Oct 6 2021, 10:43

Author Name: CNBC International TV

BNTX News

By Reuters
October 26, 2023

Pfizer, BioNtech say flu-COVID shot generates immune response

Pfizer and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the viru

By CNBC Television
October 16, 2023

Paxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan Seigerman

Evan Seigerman, BMO Capital Markets analyst, joins 'Closing Bell: Overtime' to discuss Pfizer and BioNTech cutting guidance amid Covid sales falling,

By Forbes
October 16, 2023

Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.

By Proactive Investors
October 16, 2023

Pfizer and BioNtech take big write-downs on Covid jab stocks

Covid vaccine developer BioNTech is to take a write-down of up to €900 million on its stocks of jabs following a similar provision by partner Pfize

By Market Watch
October 16, 2023

Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move

Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 i

By Reuters
October 16, 2023

BioNTech will likely take 900 mln eur write-off on Pfizer-partnered vaccines

Germany's BioNTech on Monday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner Pf

By GlobeNewsWire
October 16, 2023

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, c

By The Motley Fool
September 29, 2023

Why Pfizer and BioNTech Stocks Zoomed Higher Today

While people in this country aren't rushing in masses to get updated COVID booster vaccines, take-up has been encouraging. Many are worried about an a

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.